Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/31806
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahmed, S | - |
dc.contributor.author | Dorin, F | - |
dc.contributor.author | Satter, SM | - |
dc.contributor.author | Sarker, AR | - |
dc.contributor.author | Sultana, M | - |
dc.contributor.author | Gastanaduy, PA | - |
dc.contributor.author | Parashar, U | - |
dc.contributor.author | Tate, JE | - |
dc.contributor.author | Heffelfinger, JD | - |
dc.contributor.author | Gurley, ES | - |
dc.contributor.author | Khan, JAM | - |
dc.date.accessioned | 2025-08-23T15:57:19Z | - |
dc.date.available | 2025-08-23T15:57:19Z | - |
dc.date.issued | 2021-10-30 | - |
dc.identifier | ORCiD: Sayem Ahmed https://orcid.org/0000-0001-9499-1500 | - |
dc.identifier.citation | Ahmed, S. et al. (2021) 'The economic burden of rotavirus hospitalization among children < 5 years of age in selected hospitals in Bangladesh', Vaccine, 39 (48), pp. 7082 - 7090. doi: 10.1016/j.vaccine.2021.10.003. | en_US |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/31806 | - |
dc.description | Supplementary material is available online at: https://www.sciencedirect.com/science/article/pii/S0264410X21013104#s0090 . | en_US |
dc.description.abstract | Background: Rotavirus is a common cause of severe acute gastroenteritis among young children. Estimation of the economic burden would provide informed decision about investment on prevention strategies (e.g., vaccine and/or behavior change), which has been a potential policy discussion in Bangladesh for several years. Methods: We estimated the societal costs of children <5 years for hospitalization from rotavirus gastroenteritis (RVGE) and incidences of catastrophic health expenditure. A total of 360 children with stool specimens positive for rotavirus were included in this study from 6 tertiary hospitals (3 public and 3 private). We interviewed the caregiver of the patient and hospital staff to collect cost from patient and health facility perspectives. We estimated the economic cost considering 2015 as the reference year. Results: The total societal per-patient costs to treat RVGE in the public hospital were 126 USD (95% CI: 116–136) and total household costs were 161 USD (95% CI: 145–177) in private facilities. Direct costs constituted 38.1% of total household costs. The out-of-pocket payments for RVGE hospitalization was 23% of monthly income and 76% of households faced catastrophic healthcare expenditures due to this expense. The estimated total annual household treatment cost for the country was 10 million USD. Conclusions: A substantial economic burden of RVGE in Bangladesh was observed in this study. Any prevention of RVGE through cost-effective vaccination or/and behavioural change would contribute to substantial economic benefits to Bangladesh. | en_US |
dc.description.sponsorship | The economic burden study is part of the hospital-based rotavirus surveillance system supported by the USAID-Bangladesh, U.S. Agency for International Development, under the terms of an Interagency Agreement with U.S. Centers for Disease Control and Prevention (CDC); grant number: 1U51GH001209. | en_US |
dc.format.extent | 7082 - 7090 | - |
dc.format.medium | Print-Electronic | - |
dc.language | English | - |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.subject | economic burden | en_US |
dc.subject | rotavirus gastroenteritis | en_US |
dc.subject | diarrhea | en_US |
dc.subject | costs-of-illness | en_US |
dc.subject | catastrophic health expenditure | en_US |
dc.subject | Bangladesh | en_US |
dc.title | The economic burden of rotavirus hospitalization among children < 5 years of age in selected hospitals in Bangladesh | en_US |
dc.type | Article | en_US |
dc.date.dateAccepted | 2021-10-04 | - |
dc.identifier.doi | https://doi.org/10.1016/j.vaccine.2021.10.003 | - |
dc.relation.isPartOf | Vaccine | - |
pubs.issue | 48 | - |
pubs.publication-status | Published | - |
pubs.volume | 39 | - |
dc.identifier.eissn | 1873-2518 | - |
dc.rights.license | https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode.en | - |
dcterms.dateAccepted | 2021-10-04 | - |
dc.rights.holder | Elsevier Ltd. | - |
Appears in Collections: | Dept of Health Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ (see: https://www.elsevier.com/about/policies/sharing). | 708.1 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License